Biogen in $1.5B unsecured loan facility for Reata acquisition
panida wijitpanya

Biogen has entered intio a $1.5B unsecured loan term facility to finance its $7.3B acquisition of Reata Pharmaceuticals (RETA).

The loan is composed of a $750M 364-day tranche and a $750M three-year tranche.
JP Morgan Chase is the administrative agent for the loan.


More on Biogen

Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects
Sanofi was mystery suitor in Reata Pharma bidding war - report
Biogen And Alzheimer's Disease: Too Early To Celebrate
Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?
RBC Capital sees Biogen stock undervaluing Leqembi prospects
Biogen's Leqembi set for strong uptake based on Baird physician survey
Seeking Alphaâs Quant Rating on Biogen
Earnings data for Biogen
Dividend for Biogen